ArticleLife (Basel, Switzerland)2025
First-in-Human Application of Very High-Power Short-Duration RF Ablation for Refractory AVNRT: A Case Report.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRefractory atrioventricular nodal reentrant tachycardia (AVNRT) is a rare condition, but poses a clinical challenge after failed standard ablation. Very high-power, short-duration (vHPSD) radiofrequency (RF) ablation has not yet been explored in slow pathway ablation/modification. CASE SUMMARY: A 61-year-old woman with recurrent AVNRT despite two prior ablations and multiple antiarrhythmics underwent successful slow pathway ablation using a 90-watt, 4-s vHPSD protocol. CARTO-guided mapping localized the presumed slow pathway, followed by several 90 W applications. Transient second-degree AV block (Wenckebach type) occurred and resolved spontaneously. The patient remained arrhythmia-free at 6-month follow-up.
conclusionsThis is the first reported clinical use of 90 W/4 s RF energy for AVNRT. The vHPSD approach may offer an effective alternative for patients with refractory AVNRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.